BR112023002957A2 - Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero - Google Patents
Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamíferoInfo
- Publication number
- BR112023002957A2 BR112023002957A2 BR112023002957A BR112023002957A BR112023002957A2 BR 112023002957 A2 BR112023002957 A2 BR 112023002957A2 BR 112023002957 A BR112023002957 A BR 112023002957A BR 112023002957 A BR112023002957 A BR 112023002957A BR 112023002957 A2 BR112023002957 A2 BR 112023002957A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- hypersonia
- compound
- pharmaceutical composition
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 241000124008 Mammalia Species 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 201000003631 narcolepsy Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108050000742 Orexin Receptor Proteins 0.000 abstract 2
- 102000008834 Orexin receptor Human genes 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 229940127340 Orexin Receptor Agonists Drugs 0.000 abstract 1
- -1 bicyclo[4.1.0]heptane pyrrolidine compounds Chemical class 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Abstract
COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, E, MÉTODOS PARA TRATAR NARCOLEPSIA E PARA TRATAR HIPERSONIA EM UM SUJEITO MAMÍFERO. A presente invenção está direcionada aos compostos de biciclo[4,1,0]heptano pirrolidina de fórmula (I) que são agonistas de receptores de orexina. A presente invenção também está direcionada aos usos dos compostos aqui descritos no tratamento potencial ou prevenção de distúrbios neurológicos e psiquiátricos e doenças nas quais os receptores de orexina estão envolvidos. A presente invenção também está direcionada às composições compreendendo estes compostos. A presente invenção também está direcionada aos usos destas composições na prevenção potencial ou tratamento de tais doenças nas quais os receptores de orexina estão envolvidos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063066908P | 2020-08-18 | 2020-08-18 | |
US202163226798P | 2021-07-29 | 2021-07-29 | |
PCT/US2021/046098 WO2022040070A1 (en) | 2020-08-18 | 2021-08-16 | Bicycloheptane pyrrolidine orexin receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023002957A2 true BR112023002957A2 (pt) | 2023-04-04 |
Family
ID=77655694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023002957A BR112023002957A2 (pt) | 2020-08-18 | 2021-08-16 | Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero |
Country Status (18)
Country | Link |
---|---|
US (2) | US11680060B2 (pt) |
EP (1) | EP4200295A1 (pt) |
JP (1) | JP7443625B2 (pt) |
KR (1) | KR20230053639A (pt) |
CN (1) | CN116249697A (pt) |
AU (1) | AU2021329805B2 (pt) |
BR (1) | BR112023002957A2 (pt) |
CA (1) | CA3189908A1 (pt) |
CL (1) | CL2023000468A1 (pt) |
CO (1) | CO2023001795A2 (pt) |
CR (1) | CR20230089A (pt) |
DO (1) | DOP2023000036A (pt) |
EC (1) | ECSP23012026A (pt) |
IL (1) | IL300610A (pt) |
MX (1) | MX2023001840A (pt) |
PE (1) | PE20231384A1 (pt) |
TW (1) | TW202227417A (pt) |
WO (1) | WO2022040070A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL293240A (en) | 2019-11-25 | 2022-07-01 | Alkermes Inc | Transmutable macrocyclic compounds, preparations containing them and their uses |
US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
Family Cites Families (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2263702A (en) | 1939-01-18 | 1941-11-25 | Konstruktion Und Verwertung Au | Centrifugal clutch construction |
US3914250A (en) | 1974-08-01 | 1975-10-21 | American Home Prod | 1,4-Diazepino{8 6,5,4-jk{9 carbazoles |
US4919602A (en) | 1987-12-21 | 1990-04-24 | Janszen Arthur W | Apparatus for repairing windshields |
WO1990005525A1 (en) | 1988-11-23 | 1990-05-31 | Pfizer Inc. | Quinuclidine derivatives as substance p antagonists |
US5232929A (en) | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
US5112820A (en) | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
US5081122A (en) | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
US4973587A (en) | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
US5242930A (en) | 1991-02-11 | 1993-09-07 | Merck Sharp & Dohme Ltd. | Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy |
DE69200921T2 (de) | 1991-03-01 | 1995-05-04 | Pfizer | 1-azabicyclo[3.2.2]nonan-3-aminderivate. |
US5459270A (en) | 1991-08-20 | 1995-10-17 | Merck Sharp & Dohme Limited | Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
GB9211193D0 (en) | 1992-05-27 | 1992-07-08 | Merck Sharp & Dohme | Therapeutic agents |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5637699A (en) | 1992-06-29 | 1997-06-10 | Merck & Co., Inc. | Process for preparing morpholine tachykinin receptor antagonists |
US5387595A (en) | 1992-08-26 | 1995-02-07 | Merck & Co., Inc. | Alicyclic compounds as tachykinin receptor antagonists |
US5536716A (en) | 1992-12-11 | 1996-07-16 | Merck & Co., Inc. | Spiro piperidines and homologs which promote release of growth hormone |
US5292736A (en) | 1993-02-26 | 1994-03-08 | Sterling Winthrop Inc. | Morpholinoalkylindenes as antiglaucoma agents |
US5496833A (en) | 1993-04-13 | 1996-03-05 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
CA2203878C (en) | 1994-11-07 | 2002-06-25 | John M. Peterson | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
US5831115A (en) | 1995-04-21 | 1998-11-03 | Abbott Laboratories | Inhibitors of squalene synthase and protein farnesyltransferase |
US5739106A (en) | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
AU7692996A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Receptor antagonists |
WO1997020820A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl compounds |
WO1997020821A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
AU7692896A (en) | 1995-12-01 | 1997-06-27 | Novartis Ag | Quinazolin-2,4-diazirines as NPY receptor antagonist |
AU1328197A (en) | 1995-12-01 | 1997-06-19 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
EP0887340A4 (en) | 1996-02-06 | 2000-03-29 | Japan Tobacco Inc | CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE |
GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
CA2273102A1 (en) | 1996-12-03 | 1998-06-11 | Banyu Pharmaceutical Co., Ltd. | Urea derivatives |
CA2274592C (en) | 1996-12-12 | 2007-03-13 | Banyu Pharmaceutical Co., Ltd. | Pyrazole derivatives |
CA2274593A1 (en) | 1996-12-13 | 1998-06-18 | Banyu Pharmaceutical Co., Ltd. | Novel aminopyrazole derivatives |
US6180653B1 (en) | 1996-12-16 | 2001-01-30 | Banyu Pharmaceutical Co., Ltd. | Aminopyrazole derivatives |
EP0971588B1 (en) | 1997-01-21 | 2004-03-17 | Smithkline Beecham Corporation | Novel cannabinoid receptor modulators |
WO1998033765A1 (en) | 1997-02-04 | 1998-08-06 | E.I. Du Pont De Nemours And Company | Fungicidal carboxamides |
AU735137B2 (en) | 1997-02-21 | 2001-07-05 | Bayer Intellectual Property Gmbh | Arylsulphonamides and analogues and their use for the treatment and neurovegetative disorders |
WO1998040356A1 (fr) | 1997-03-12 | 1998-09-17 | Banyu Pharmaceutical Co., Ltd. | Medicaments contenant des derives d'aminopyridine comme ingredient actif |
JP2001516361A (ja) | 1997-03-18 | 2001-09-25 | スミスクライン・ビーチャム・コーポレイション | 新規カンナビノイド受容体作動薬 |
FR2761265B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates |
FR2761266B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
AU7079498A (en) | 1997-04-23 | 1998-11-13 | Banyu Pharmaceutical Co., Ltd. | Neuropeptide y receptor antagonist |
US6001836A (en) | 1997-05-28 | 1999-12-14 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: cyanoguanidine derivatives |
WO1999002499A1 (fr) | 1997-07-11 | 1999-01-21 | Japan Tobacco Inc. | Composes quinoline et utilisations de ceux-ci en medecine |
WO1999015516A1 (fr) | 1997-09-25 | 1999-04-01 | Banyu Pharmaceutical Co., Ltd. | Nouveaux antagonistes des recepteurs de neuropeptides y |
WO1999027965A1 (fr) | 1997-11-28 | 1999-06-10 | Banyu Pharmaceutical Co., Ltd. | Agents anti-hyperlipemiques |
JP2002510688A (ja) | 1998-04-02 | 2002-04-09 | ニューロゲン コーポレイション | アミノアルキル置換9H−ピリジノ[2,3−b]インドールおよび9H−ピリミジノ[4,5−b]インドール誘導体 |
DE69918296T2 (de) | 1998-04-29 | 2005-08-04 | Ortho-Mcneil Pharmaceutical, Inc. | N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen |
US6329395B1 (en) | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
DE19837627A1 (de) | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
HN1998000027A (es) | 1998-08-19 | 1999-06-02 | Bayer Ip Gmbh | Arilsulfonamidas y analagos |
US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
US6337332B1 (en) | 1998-09-17 | 2002-01-08 | Pfizer Inc. | Neuropeptide Y receptor antagonists |
ATE314371T1 (de) | 1998-11-10 | 2006-01-15 | Merck & Co Inc | Spiro-indole als y5-rezeptor antagonisten |
US6340683B1 (en) | 1999-04-22 | 2002-01-22 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (triazines) |
AU775166B2 (en) | 1999-04-22 | 2004-07-22 | H. Lundbeck A/S | Selective NPY (Y5) antagonists |
WO2000068197A1 (en) | 1999-05-05 | 2000-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS |
US6291476B1 (en) | 1999-05-12 | 2001-09-18 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
WO2001002379A1 (en) | 1999-06-30 | 2001-01-11 | Synaptic Pharmaceutical Corporation | Selective npy (y5) antagonists |
AU6000900A (en) | 1999-07-23 | 2001-02-13 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
WO2001009120A1 (en) | 1999-07-28 | 2001-02-08 | Ortho-Mcneil Pharmaceutical, Inc. | Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders |
US6462053B1 (en) | 1999-08-20 | 2002-10-08 | Banyu Pharmaceutical Co., Ltd. | Spiro compounds |
TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
WO2001021577A2 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
CA2383147A1 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Mch antagonists |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
AU7737900A (en) | 1999-09-30 | 2001-04-30 | Neurogen Corporation | Amino substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines |
CN1377356A (zh) | 1999-09-30 | 2002-10-30 | 纽罗杰有限公司 | 亚烷基二胺取代的杂环 |
US6372743B1 (en) | 1999-09-30 | 2002-04-16 | Neurogen Corporation | Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines |
PL356485A1 (en) | 1999-12-16 | 2004-06-28 | Schering Corporation | Substituted imidazole neuropeptide y y5 receptor antagonists |
AU2001228325A1 (en) | 2000-02-01 | 2001-08-14 | Novo-Nordisk A/S | Use of compounds for the regulation of food intake |
AU2001234958A1 (en) | 2000-02-11 | 2001-08-20 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
AU2001234128B2 (en) | 2000-02-22 | 2004-11-11 | Banyu Pharmaceutical Co., Ltd. | Novel imidazoline compounds |
US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
FR2805818B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
FR2805810B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
FR2805817B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
EP1132389A1 (en) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
EP1142886A1 (en) | 2000-04-07 | 2001-10-10 | Aventis Pharma Deutschland GmbH | Percyquinnin, a process for its production and its use as a pharmaceutical |
DE60142961D1 (de) | 2000-04-28 | 2010-10-14 | Takeda Pharmaceutical | Antagonisten des melanin-konzentrierenden hormons |
GB0010757D0 (en) | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
GB0011013D0 (en) | 2000-05-09 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
US6444675B2 (en) | 2000-05-10 | 2002-09-03 | Bristol-Myers Squibb Company | 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists |
WO2001085173A1 (en) | 2000-05-10 | 2001-11-15 | Bristol-Myers Squibb Company | Alkylamine derivatives of dihydropyridine npy antagonists |
US6432960B2 (en) | 2000-05-10 | 2002-08-13 | Bristol-Myers Squibb Company | Squarate derivatives of dihydropyridine NPY antagonists |
AU2001256733A1 (en) | 2000-05-16 | 2001-11-26 | Takeda Chemical Industries Ltd. | Melanin-concentrating hormone antagonist |
WO2001087335A2 (en) | 2000-05-17 | 2001-11-22 | Eli Lilly And Company | Method for selectively inhibiting ghrelin action |
US6391881B2 (en) | 2000-05-19 | 2002-05-21 | Bristol-Myers Squibb Company | Thiourea derivatives of dihydropyridine NPY antagonists |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
CA2384041A1 (en) | 2000-07-05 | 2002-01-24 | Synaptic Pharmaceuticals Corporation | Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
US6569861B2 (en) | 2000-07-06 | 2003-05-27 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
WO2002008250A2 (en) | 2000-07-24 | 2002-01-31 | Ardana Bioscience Limited | Ghrelin antagonists |
AU8395501A (en) | 2000-07-31 | 2002-02-13 | Hoffmann La Roche | Piperazine derivatives |
EP1322628A2 (en) | 2000-09-14 | 2003-07-02 | Schering Corporation | Substituted urea neuropeptide y y5 receptor antagonists |
EP1326851B1 (en) | 2000-10-13 | 2004-06-30 | Eli Lilly And Company | Substituted dipeptides as growth hormone secretagogues |
WO2002044152A1 (en) | 2000-10-16 | 2002-06-06 | F. Hoffmann-La Roche Ag | Indoline derivatives and their use as 5-ht2 receptor ligands |
WO2002036596A2 (en) | 2000-11-03 | 2002-05-10 | Wyeth | CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES |
EP1335907B1 (en) | 2000-11-20 | 2010-06-09 | Biovitrum AB (publ) | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor |
ES2328671T3 (es) | 2000-11-20 | 2009-11-17 | Biovitrum Ab (Publ) | Compuestos de piperazilpirazinas como antagonistas del receptor de serotonina 5-ht2. |
WO2002048152A2 (en) | 2000-12-12 | 2002-06-20 | Neurogen Corporation | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines |
GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
AR035520A1 (es) | 2000-12-21 | 2004-06-02 | Schering Corp | Compuestos heteroarilo urea que son neuropeptidos y antagonistas de los receptores y5 del neuropeptido y, composiciones farmaceuticas, un proceso para su preparacion, uso de dichos compuestos y composiciones para la manufactura de medicamentos |
ATE302185T1 (de) | 2000-12-22 | 2005-09-15 | Schering Corp | Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität |
KR100539143B1 (ko) | 2000-12-27 | 2005-12-26 | 에프. 호프만-라 로슈 아게 | 인돌 유도체 및 그의 5-ht2b 및 5-ht2c 수용체리간드로서의 용도 |
US7034039B2 (en) | 2001-02-02 | 2006-04-25 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
AU2002247367B2 (en) | 2001-03-21 | 2005-10-27 | Pharmacopeia Drug Discovery, Inc. | Aryl and biaryl compounds having MCH modulatory activity |
US6900329B2 (en) | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
PT1373216E (pt) | 2001-03-22 | 2005-05-31 | Solvay Pharm Bv | Derivados de 4,5-diidro-1h-pirazol que possuem actividade antagonista de cb1 |
CA2443672C (en) | 2001-04-12 | 2011-03-29 | Pharmacopeia, Inc. | Aryl and biaryl piperidines used as mch antagonists |
US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6953801B2 (en) | 2001-05-22 | 2005-10-11 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
WO2002094825A1 (fr) | 2001-05-22 | 2002-11-28 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de spiropiperidine |
JP2004535433A (ja) | 2001-06-20 | 2004-11-25 | メルク エンド カムパニー インコーポレーテッド | 糖尿病治療用のジペプチジルペプチダーゼ阻害薬 |
WO2003000181A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
DE60222667T2 (de) | 2001-06-27 | 2008-07-17 | Smithkline Beecham Corp. | Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren |
DE60221983T2 (de) | 2001-06-27 | 2008-05-15 | Smithkline Beecham Corp. | Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren |
EP1399420B1 (en) | 2001-06-27 | 2007-12-05 | SmithKline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
RU2299066C2 (ru) | 2001-06-27 | 2007-05-20 | Пробиодруг Аг | Новые ингибиторы дипептидилпептидазы iv и их применение в качестве противораковых агентов |
ATE388951T1 (de) | 2001-07-03 | 2008-03-15 | Novo Nordisk As | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes |
MXPA03011886A (es) | 2001-07-05 | 2005-03-07 | Lundbeck & Co As H | Piperidinias anilinicas sustituidas como antagonistas selectivos de mch. |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
BRPI0104510B8 (pt) | 2001-07-27 | 2021-05-25 | Embrapa Pesquisa Agropecuaria | peptídeos antibióticos da família das phylloseptinas isolados da secreção da pele de phylloseptina hypocondrialis e composição antimicrobiana relacionada |
MXPA04001144A (es) | 2001-08-07 | 2004-07-08 | Banyu Pharma Co Ltd | Compuestos espiro. |
JP2005320249A (ja) | 2002-05-01 | 2005-11-17 | Banyu Pharmaceut Co Ltd | 2−アミノピラジン誘導体の製造方法 |
AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US6869966B2 (en) | 2002-09-30 | 2005-03-22 | Banyu Pharmaceutical Co., Ltd. | N-substituted-2-oxodihydropyridine derivatives |
MY134457A (en) | 2002-11-22 | 2007-12-31 | Merck & Co Inc | Substituted amides |
JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
AU2004252109B2 (en) | 2003-06-11 | 2010-04-08 | Merck Sharp & Dohme Corp. | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
JP5976011B2 (ja) | 2011-04-05 | 2016-08-23 | 武田薬品工業株式会社 | スルホンアミド誘導体およびその用途 |
EA036166B1 (ru) | 2016-02-04 | 2020-10-08 | Такеда Фармасьютикал Компани Лимитед | Замещенное пиперидиновое соединение и его применение |
EP3594203B1 (en) | 2017-03-08 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
EP3594202B1 (en) | 2017-03-08 | 2021-08-11 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
EP3661923A1 (en) | 2017-08-03 | 2020-06-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
JP7189140B2 (ja) | 2017-08-03 | 2022-12-13 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
EP3816153B1 (en) | 2018-06-29 | 2023-10-18 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
EP3816154A4 (en) | 2018-06-29 | 2022-03-30 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF |
JP7408569B2 (ja) | 2018-12-12 | 2024-01-05 | 武田薬品工業株式会社 | 複素環化合物 |
JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
EP3917616A1 (en) | 2019-01-31 | 2021-12-08 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
WO2020167706A1 (en) * | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
-
2021
- 2021-08-16 IL IL300610A patent/IL300610A/en unknown
- 2021-08-16 AU AU2021329805A patent/AU2021329805B2/en active Active
- 2021-08-16 US US17/402,932 patent/US11680060B2/en active Active
- 2021-08-16 US US18/040,896 patent/US20230365533A1/en active Pending
- 2021-08-16 EP EP21766336.8A patent/EP4200295A1/en active Pending
- 2021-08-16 WO PCT/US2021/046098 patent/WO2022040070A1/en active Application Filing
- 2021-08-16 JP JP2023511949A patent/JP7443625B2/ja active Active
- 2021-08-16 MX MX2023001840A patent/MX2023001840A/es unknown
- 2021-08-16 KR KR1020237008981A patent/KR20230053639A/ko unknown
- 2021-08-16 CA CA3189908A patent/CA3189908A1/en active Pending
- 2021-08-16 CR CR20230089A patent/CR20230089A/es unknown
- 2021-08-16 BR BR112023002957A patent/BR112023002957A2/pt unknown
- 2021-08-16 TW TW110130112A patent/TW202227417A/zh unknown
- 2021-08-16 CN CN202180067840.8A patent/CN116249697A/zh active Pending
- 2021-08-16 PE PE2023000316A patent/PE20231384A1/es unknown
-
2023
- 2023-02-15 CL CL2023000468A patent/CL2023000468A1/es unknown
- 2023-02-16 EC ECSENADI202312026A patent/ECSP23012026A/es unknown
- 2023-02-17 DO DO2023000036A patent/DOP2023000036A/es unknown
- 2023-02-17 CO CONC2023/0001795A patent/CO2023001795A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230365533A1 (en) | 2023-11-16 |
EP4200295A1 (en) | 2023-06-28 |
CL2023000468A1 (es) | 2023-08-04 |
US11680060B2 (en) | 2023-06-20 |
AU2021329805B2 (en) | 2024-02-29 |
KR20230053639A (ko) | 2023-04-21 |
CO2023001795A2 (es) | 2023-03-17 |
CN116249697A (zh) | 2023-06-09 |
US20220056017A1 (en) | 2022-02-24 |
WO2022040070A1 (en) | 2022-02-24 |
MX2023001840A (es) | 2023-03-13 |
CA3189908A1 (en) | 2022-02-24 |
DOP2023000036A (es) | 2023-04-16 |
IL300610A (en) | 2023-04-01 |
AU2021329805A1 (en) | 2023-03-09 |
TW202227417A (zh) | 2022-07-16 |
JP2023533604A (ja) | 2023-08-03 |
JP7443625B2 (ja) | 2024-03-05 |
ECSP23012026A (es) | 2023-03-31 |
PE20231384A1 (es) | 2023-09-12 |
CR20230089A (es) | 2023-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023002957A2 (pt) | Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero | |
BR0206435A (pt) | Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos | |
BR112021022778A2 (pt) | Compostos e métodos para o tratamento de covid-19 | |
BRPI0916235A8 (pt) | Composto, composição farmacêutica, e, uso do composto ou da composição | |
BR112022002520A2 (pt) | Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer | |
BRPI0409601A (pt) | composto, composição farmacêutica, e, uso do composto | |
BR0013899A (pt) | Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral | |
BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
BR112022025201A2 (pt) | Compostos de sulfonamida de di-hidroquinolina de ciclobutila | |
BRPI0513858B8 (pt) | compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende | |
BR9909597A (pt) | Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas | |
BR112022021976A2 (pt) | Composto, e, composição farmacêutica compreendendo um composto | |
BR112012025590A2 (pt) | análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119 | |
CR20230256A (es) | Compuestos farmacéuticos | |
MX2022012575A (es) | Compuestos para usarse para tratar la enfermedad de huntington. | |
BR112022025946A2 (pt) | Composto, composição farmacêutica e método de tratamento de uma doença | |
BR0115306A (pt) | Composto, prodroga, composição farmacêutica, agente para diminuir androgênio, método para a produção de um composto, e, sal diastereomérico | |
BR112023000588A2 (pt) | Derivados de piridazina como inibidores de alk5 e/ou alk4 | |
BR112023015425A2 (pt) | Derivados de uracila como inibidores de trpa1 | |
BR112022013488A2 (pt) | Pirazolo-pirimidinas substituídas e seu uso | |
BR112019024804A2 (pt) | compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas | |
BR112022009942A2 (pt) | Derivados de 1,2,4-oxadiazol como agonistas do receptor x do fígado | |
BR112022018173A2 (pt) | Composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, composto para o uso e uso de um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo | |
BR9808249A (pt) | Composição farmacêutica, processos para tratar câncer em um mamìfero e para a manufatura de um medicamento para o tratamento de câncer em um mamìfero, e, uso de um composto | |
BRPI0415113A (pt) | compostos de lactama condensados |